Control Empresarial De Capital Acquires 100,000 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK - Get Free Report) insider Control Empresarial De Capital purchased 100,000 shares of the company's stock in a transaction on Wednesday, April 16th. The stock was acquired at an average price of $0.75 per share, with a total value of $75,000.00. Following the completion of the purchase, the insider now directly owns 73,430,330 shares in the company, valued at $55,072,747.50. This trade represents a 0.14 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Control Empresarial De Capital also recently made the following trade(s):

• On Monday, April 14th, Control Empresarial De Capital purchased 268,105 shares of ProKidney stock. The stock was bought at an average price of $0.73 per share, for a total transaction of $195,716.65.
• On Thursday, April 10th, Control Empresarial De Capital acquired 1,032,218 shares of ProKidney stock. The shares were bought at an average cost of $0.61 per share, with a total value of $629,652.98.

ProKidney Price Performance

Shares of PROK stock traded up $0.16 during trading hours on Wednesday, hitting $0.91. The stock had a trading volume of 1,881,771 shares, compared to its average volume of 680,869. The stock's 50-day moving average price is $0.99 and its two-hundred day moving average price is $1.49. ProKidney Corp. has a one year low of $0.46 and a one year high of $4.44. The stock has a market capitalization of $266.38 million, a price-to-earnings ratio of -1.65 and a beta of 1.52.

ProKidney (NASDAQ:PROK - Get Free Report) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). The business had revenue of $0.08 million during the quarter. As a group, equities research analysts predict that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ProKidney

A number of hedge funds have recently bought and sold shares of PROK. Geode Capital Management LLC raised its position in shares of ProKidney by 102.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,203,934 shares of the company's stock valued at $4,232,000 after buying an additional 1,112,933 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in ProKidney during the fourth quarter worth approximately $961,000. State Street Corp increased its stake in ProKidney by 16.2% during the third quarter. State Street Corp now owns 1,428,318 shares of the company's stock worth $2,742,000 after acquiring an additional 198,836 shares during the last quarter. Bleichroeder LP raised its position in ProKidney by 8.4% during the fourth quarter. Bleichroeder LP now owns 2,000,000 shares of the company's stock valued at $3,380,000 after purchasing an additional 155,000 shares during the period. Finally, Barclays PLC lifted its stake in shares of ProKidney by 575.7% in the 3rd quarter. Barclays PLC now owns 146,321 shares of the company's stock valued at $281,000 after purchasing an additional 124,667 shares during the last quarter. Hedge funds and other institutional investors own 51.59% of the company's stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.